# **Data Changes for the CCDD JULY Release Candidate 2024**

## **Based on the QA Release Generation** 2024-07-02

|  |  |
| --- | --- |
| Data entered by | J.Hutsul |
| Data checked by |  |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] |  |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
|  | [NONE] |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  |  |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
| 9013109 | eptifibatide 75 mg per 100 mL solution for injection vial | 9015044 |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9005253 | benzalkonium chloride 0.13 % and lidocaine 4 % cutaneous cream |
| 9004273 | diphenhydramine hydrochloride 2 % and zinc acetate 0.1 % cutaneous spray |
| 9005937 | palbociclib 75 mg oral capsule |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. The product has been transferred from DPD to LNHPD.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Code permanence – name changes**

The following MP concept(s) need to keep its/their existing mp\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **mp\_code (to keep)** | **mp \_formal\_name** | **mp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 60149 | 2236859 | AGRYLIN (anagrelide (anagrelide hydrochloride) 0.5 mg oral capsule) TAKEDA CANADA INC | Cancelled post-market Expiry 2024.06.30 |
| 10828 | 882801 | APO-PRAZO TAB 1MG (prazosin (prazosin hydrochloride) 1 mg oral tablet) APOTEX INC | Dormant 2024.04.18 |
| 10829 | 882828 | APO-PRAZO TAB 2MG (prazosin (prazosin hydrochloride) 2 mg oral tablet) APOTEX INC | Dormant 2024.04.11 |
| 76655 | 2280876 | BENADRYL SPRAY (diphenhydramine hydrochloride 2 % and zinc acetate 0.1 % cutaneous spray) MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | Cancelled post-market Expiry 2024.06.30 |
| 72553 | 2248217 | BLEMISH GEL 5% (benzoyl peroxide 5 % cutaneous gel) KAMINS DERMATOLOGICS INC | Dormant 2024.06.04 |
| 89066 | 2405903 | CHILDREN'S COUGH & COLD RELIEF (dextromethorphan hydrobromide 7.5 mg per 5 mL and pseudoephedrine hydrochloride 15 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2026.06.26 |
| 16498 | 2053632 | CHLORHEXIDINE GLUCONATE SOLUTION USP 20% (chlorhexidine gluconate 20 % cutaneous solution) GERMIPHENE CORPORATION | Dormant 2024.06.27 |
| 89068 | 2405938 | COUGH & CHEST CONGESTION (dextromethorphan hydrobromide 15 mg per 5 mL and guaifenesin 100 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 89067 | 2405911 | COUGH & CHEST CONGESTION EXTRA STRENGTH (dextromethorphan hydrobromide 15 mg per 5 mL and guaifenesin 200 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 89064 | 2405873 | COUGH & COLD RELIEF (dextromethorphan hydrobromide 15 mg per 5 mL and guaifenesin 100 mg per 5 mL and pseudoephedrine hydrochloride 30 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 89065 | 2405881 | COUGH & COLD RELIEF EXTRA STRENGTH (dextromethorphan hydrobromide 15 mg per 5 mL and guaifenesin 200 mg per 5 mL and pseudoephedrine hydrochloride 30 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 95360 | 2465426 | D-FORTE (ergocalciferol 50000 unit oral capsule) EURO-PHARM INTERNATIONAL CANADA INC | Dormant 2024.06.14 |
| 874 | 30570 | DALACIN C 150 MG (clindamycin (clindamycin hydrochloride) 150 mg oral capsule) PFIZER CANADA ULC | Dormant 2022.08.01 |
| 89069 | 2405946 | DRY COUGH RELIEF EXTRA STRENGTH (dextromethorphan hydrobromide 15 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 86080 | 2375397 | FOOTWORKS HEALTHY ANTIFUNGAL SPRAY FOR ATHLETE'S FOOT (tolnaftate 1 % cutaneous spray) THE AVON COMPANY CANADA LIMITED | Dormant 2024.06.19 |
| 88252 | 2397587 | FOOTWORKS HEALTHY CRACKED HEEL CREAM (benzalkonium chloride 0.13 % and lidocaine 4 % cutaneous cream) THE AVON COMPANY CANADA LIMITED | Dormant 2024.06.19 |
| 12713 | 1930087 | GERMI STAT GEL 4% (chlorhexidine gluconate 4 % cutaneous gel) GERMIPHENE CORPORATION | Dormant 2024.06.27 |
| 84557 | 2360608 | HYDROCHLOROTHIAZIDE (hydrochlorothiazide 50 mg oral tablet) SANIS HEALTH INC | Dormant 2024.06.27 |
| 93969 | 2453150 | IBRANCE (palbociclib 75 mg oral capsule) PFIZER CANADA ULC | Cancelled post-market Expiry 2024.01.31 |
| 89063 | 2405865 | MUCUS & PHLEGM RELIEF EXTRA STRENGTH (guaifenesin 200 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 89062 | 2405857 | MUCUS & PHLEGM RELIEF WITH COUGH CONTROL EXTRA STRENGTH (dextromethorphan hydrobromide 15 mg per 5 mL and guaifenesin 200 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 99961 | 2510383 | POLY ANTIBIOTIC OINTMENT (bacitracin 500 unit per g and polymyxin B (polymyxin B sulfate) 10000 unit per g cutaneous ointment) THE AVON COMPANY CANADA LIMITED | Dormant 2024.06.19 |
| 82855 | 2343061 | PROPAFENONE (propafenone hydrochloride 300 mg oral tablet) SANIS HEALTH INC | Cancelled post-market Expiry 2024.02.29 |
| 77475 | 2289385 | TOTAL COLD AND FLU EXTRA STRENGTH (acetaminophen 1000 mg per 30 mL and dextromethorphan hydrobromide 30 mg per 30 mL and guaifenesin 200 mg per 30 mL and pseudoephedrine hydrochloride 60 mg per 30 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | Dormant 2024.06.26 |
| 43386 | 2223716 | ZITHROMAX - PWS ORL 100MG/5ML (azithromycin 100 mg per 5 mL oral suspension) PFIZER CANADA ULC | Dormant 2024.05.01 |

## **Exclusion List (on GitHub)**

The following changes have been made to the Exclusion List for the MAY 2024 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Exclusion List are as follows:  
ACTION is either:

* STAY on Exclusion List
* ADD to Exclusion List
* REMOVE from Exclusion List

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 7606e1a96d2ac94e7ff92db13645c067 | eptifibatide 75 mg per 100 mL solution for injection vial | 102949 | 02540819 | EPTIFIBATIDE INJECTION (eptifibatide 75 mg per 100 mL solution for injection vial) JUNO PHARMACEUTICALS CORP. | REMOVE |
| a30d007d8eb894ed1b8e493a5447e04b | irinotecan hydrochloride 20 mg per mL solution for injection | 93881 | 02452421 | IRINOTECAN HYDROCHLORIDE INJECTION, USP (irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20 mg per mL solution for injection) GENERIC MEDICAL PARTNERS INC | REMOVE |
| eeb594428066966a2e013d25880ac0f7 | lacosamide 10 mg per mL solution for injection | 102997 | 02541343 | LACOSAMIDE INJECTION, USP (lacosamide 10 mg per mL solution for injection) HIKMA CANADA LIMITED | REMOVE |
| 2df4fbc8cc96d809720c7badc3eb6a21 | denosumab 120 mg per 1.7 mL solution for injection | 103450 | 02545764 | WYOST (denosumab 120 mg per 1.7 mL solution for injection) SANDOZ CANADA INCORPORATED | ADD |